Desmosomal Dysfunction Due to Mutations in Desmoplakin Causes Arrhythmogenic Right Ventricular Dysplasia/cardiomyopathy
Overview
Authors
Affiliations
Arrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVD/C) is characterized by progressive degeneration of the right ventricular myocardium, ventricular arrhythmias, fibrous-fatty replacement, and increased risk of sudden death. Mutations in 6 genes, including 4 encoding desmosomal proteins (Junctional plakoglobin (JUP), Desmoplakin (DSP), Plakophilin 2, and Desmoglein 2), have been identified in patients with ARVD/C. Mutation analysis of 66 probands identified 4 variants in DSP; V30M, Q90R, W233X, and R2834H. To establish a cause and effect relationship between those DSP missense mutations and ARVD/C, we performed in vitro and in vivo analyses of the mutated proteins. Unlike wild-type (WT) DSP, the N-terminal mutants (V30M and Q90R) failed to localize to the cell membrane in desomosome-forming cell line and failed to bind to and coimmunoprecipitate JUP. Multiple attempts to generate N-terminal DSP (V30M and Q90R) cardiac-specific transgenes have failed: analysis of embryos revealed evidence of profound ventricular dilation, which likely resulted in embryonic lethality. We were able to develop transgenic (Tg) mice with cardiac-restricted overexpression of the C-terminal mutant (R2834H) or WT DSP. Whereas mice overexpressing WT DSP had no detectable histologic, morphological, or functional cardiac changes, the R2834H-Tg mice had increased cardiomyocyte apoptosis, cardiac fibrosis, and lipid accumulation, along with ventricular enlargement and cardiac dysfunction in both ventricles. These mice also displayed interruption of DSP-desmin interaction at intercalated discs (IDs) and marked ultra-structural changes of IDs. These data suggest DSP expression in cardiomyocytes is crucial for maintaining cardiac tissue integrity, and DSP abnormalities result in ARVD/C by cardiomyocyte death, changes in lipid metabolism, and defects in cardiac development.
EPAS1 induction drives myocardial degeneration in desmoplakin-cardiomyopathy.
Kyriakopoulou E, van Kampen S, Wehrens M, Han S, de Ruiter H, Monshouwer-Kloots J iScience. 2025; 28(3):111895.
PMID: 40034852 PMC: 11872638. DOI: 10.1016/j.isci.2025.111895.
Arrhythmogenic Right Ventricular Cardiomyopathy: A Comprehensive Review.
Shaikh T, Nguyen D, Dugal J, DiCaro M, Yee B, Houshmand N J Cardiovasc Dev Dis. 2025; 12(2).
PMID: 39997505 PMC: 11855979. DOI: 10.3390/jcdd12020071.
Foo B, Amedei H, Kaur S, Jaawan S, Boshnakovska A, Gall T PLoS One. 2024; 19(10):e0311203.
PMID: 39446877 PMC: 11501035. DOI: 10.1371/journal.pone.0311203.
Cell-cell interactions in the heart: advanced cardiac models and omics technologies.
Tan S, Yang J, Hu S, Lei W Stem Cell Res Ther. 2024; 15(1):362.
PMID: 39396018 PMC: 11470663. DOI: 10.1186/s13287-024-03982-z.
Badowski C, Benny P, Verma C, Lane E Sci Rep. 2024; 14(1):23206.
PMID: 39369039 PMC: 11455855. DOI: 10.1038/s41598-024-73705-0.